Effects of Various Selective Phosphodiesterase Inhibitors on Relaxation and Cyclic Nucleotide Contents in Porcine Iris Sphincter

Total Page:16

File Type:pdf, Size:1020Kb

Effects of Various Selective Phosphodiesterase Inhibitors on Relaxation and Cyclic Nucleotide Contents in Porcine Iris Sphincter FULL PAPER Pharmacology Effects of Various Selective Phosphodiesterase Inhibitors on Relaxation and Cyclic Nucleotide Contents in Porcine Iris Sphincter Takuya YOGO1), Takeharu KANEDA2), Yoshinori NEZU1), Yasuji HARADA1), Yasushi HARA1), Masahiro TAGAWA1), Norimoto URAKAWA2) and Kazumasa SHIMIZU2) 1)Laboratories of Veterinary Surgery and 2)Veterinary Pharmacology, Nippon Veterinary and Life Science University, 7–1 Kyonan-cho 1– chome, Musashino, Tokyo 180–8602, Japan (Received 26 March 2009/Accepted 1 July 2009) ABSTRACT. The effects of various selective phosphodiesterase (PDE) inhibitors on muscle contractility and cyclic nucleotide contents in porcine iris sphincter were investigated. Forskolin and sodium nitroprusside inhibited carbachol (CCh)-induced contraction in a concen- tration-dependent manner. Various selective PDE inhibitors, vinpocetine (type 1), erythro -9-(2-hydroxy-3-nonyl)adenine (EHNA, type 2), milrinone (type 3), Ro20–1724 (type 4) and zaprinast (type 5), also inhibited CCh-induced contraction in a concentration-dependent manner. The rank order of potency of IC50 was zaprinast > Ro20–1724 > EHNA milrinone > vinpocetine. In the presence of CCh (0.3 M), vinpocetine, milrinone and Ro20–1724 increased cAMP, but not cGMP, contents. In contrast, zaprinast and EHNA both increased cGMP, but not cAMP, contents. This indicates that vinpocetine-, milrinone- and Ro20–1724-induced relaxation is correlated with cAMP, while EHNA- and zaprinast- induced relaxation is correlated with cGMP in porcine iris sphincter. KEY WORDS: cAMP, cGMP, iris sphincter, PDE inhibitor, smooth muscle. J. Vet. Med. Sci. 71(11): 1449–1453, 2009 Cyclic nucleotides are important secondary messengers, chol (CCh)-induced contraction of porcine iris sphincter and are associated with smooth muscle relaxation [7]. induced by selective PDE (type1–5) inhibitors. Cyclic nucleotides are synthesized by adenyl cyclase or gua- nylyl cyclase and degraded by phosphodiesterases (PDEs). MATERIALS AND METHODS In the smooth muscles of the iris-ciliary body, it has been suggested that -adrenoceptor agonists [22, 24] and Muscle preparations and tension measurement: Eyes adrenomedullin [26] increase cAMP accumulation by stim- from adult pigs of either sex were obtained from a local ulating adenyl cyclase, and that atrial natriuretic peptide [9] abattoir. Two strips of iris sphincter muscle were cut from and nitric oxide [16] increase cGMP accumulation by stim- each eye (ciliary margin removed). The muscle strips were ulating guanylyl cyclase. incubated with physiological salt solution (PSS) containing Currently, PDEs are classified into 11 families [3, 10, 27] (in mM): NaCl, 136.8; KCl, 5.4; CaCl2, 2.5; MgCl2, 1.0; and selective PDE inhibitors have been identified [4]. It has NaHCO3, 11.9; and glucose, 5.6. PSS was aerated with 95% been reported that M&B 22948 (zaprinast, type5 inhibitor) O2 and 5% CO2 to adjust pH to 7.2 at 37C. Muscle tension inhibited the carbachol-induced contraction in bovine iris was recorded isometrically. One end of each strip was sphincter muscle [2]. However, to our knowledge, there bound to a glass holder and the other end was connected by have been no reports that compared the potency of maximal a silk thread to a strain-gauge transducer (TB-611T; Nihon relaxation of various selective PDE inhibitors-induced- Kohden, Tokyo, Japan) in an organ bath containing PSS relaxation in iris smooth muscle. with a resting tension of 0.5 g. Muscle strips were equili- The angle closure glaucoma is a main pathologic condi- brated for 30 min in order to obtain stable contractility tion with the elevation in intraocular pressure because of iri- induced by hyperosmotic 65 mM KCl. docorneal angle obstraction. When iridocorneal angle Assay of cGMP and cAMP contents: The cGMP and obstraction, the play of iris and ciliary muscle is also cAMP contents of muscle strips were measured by enzyme changed. To study the influence of PDE (type1–5) inhibi- immunoassay. After incubation of the strips with vinpocet- tors in the iris and ciliary muscle contraction may not only ine, EHNA, milrinone, Ro20–1724 or zaprinast for 10 min clarify the mechanism of cAMP or cGMP with PDE in the presence of CCh (0.3 M), the strips were rapidly fro- isozyme, but also contributes to the development of novel zen in liquid nitrogen and stored at –80C until homogeniza- antiglaucoma drug. tion in 6% trichloroacetic acid (0.4 ml). Homogenates were In the present study, we investigated the relationship centrifuged at 3000 g for 15 min and the supernatant was between relaxation and cyclic nucleotide contents in carba- washed with 1.5 ml of water-saturated diethylether 4 times; the cGMP and cAMP contents of the strips were then *CORRESPONDENCE TO: YOGO, T., Laboratory of Veterinary Surgery (e-mail: [email protected]), KANEDA, T., Laboratory of Veteri- assayed using enzyme immunoassay kits (GE Healthcare, nary Pharmacology, (e-mail: [email protected]), Nippon Vet- Buckinghamshire, UK). The cGMP and cAMP contents erinary and Life Science University, 7–1 Kyonan-cho 1-chome, were expressed in terms of picomole per gram wet weight of Musashino, Tokyo 180–8602, Japan. 1450 T. YOGO ET AL. tissue. Chemicals: The chemicals used were forskolin, sodium nitroprusside (SNP), milrinone, zaprinast, CCh (Sigma, St. Louis, MO, U.S.A.), vinpocetine, erythro-9-(2-hydroxy-3- nonyl)adenine•HCl (EHNA) (BIOMOL Research Laborato- ries, Plymouth Meeting, PA, U.S.A.) and Ro20–1724 (LC Laboratories, New Boston, MA, U.S.A.). Vinpocetine crys- tallizes if the concentration exceeds 30 M in PSS; there- fore, we used vinpocetine at below 30 M in the present experiments. Statistics: Concentration-response curve for each inhibi- tor was fitted to a logistic equation using MS Excel; the fit- ting parameter was IC50. Values are expressed as means S.E.M. and statistical analyses were performed by Student’s t-test. RESULTS Fig. 1. Effects of forskolin and sodium nitroprusside on the Effects of forskolin, and SNP on CCh-induced contrac- contraction induced by 0.3 M carbachol (CCh) in porcine iris tion: When the contractile response induced by 0.3 M CCh sphincter. Preparations were precontracted with CCh, and the reached a steady level at about 15–20 min after addition, indicated agents were added cumulatively. The maximum con- forskolin, an adenyl cyclase activator, or SNP, a soluble traction induced by 0.3 M CCh in the absence of these agents was taken as 100%. Each point represents the mean of 6–7 guanylyl cyclase activator, was applied cumulatively. The preparations. Vertical bars indicate S.E.M. threshold concentrations of forskolin and SNP to induce the relaxation of the iris sphincter were 0.1 M and 0.03 M, respectively, and both inhibited CCh-induced contraction in a concentration-dependent manner (Fig. 1). The concentra- tions of forskolin and SNP producing 50% relaxation (IC50) of CCh-induced contraction were 0.68 (0.51–0.89) or 0.053 (0.045–0.061) M, respectively. Based on IC50 and maxi- mum inhibition, SNP is more potent than forskolin in the porcine iris sphincter (P<0.01). Effects of various selective PDE inhibitors on CCh- induced contraction: When the contractile response induced by 0.3 M CCh reached a steady level at about 15–20 min after application, each PDE inhibitor was added cumula- tively. Vinpocetine (type 1), EHNA (type 2), milrinone (type 3), Ro20–1724 (type 4) and zaprinast (type 5) inhib- ited CCh-induced contraction in a concentration-dependent manner (Fig. 2). The IC50 and maximum relaxation concen- trations of these inhibitors are shown in Table 1. The rank orders for the relaxant effects of IC50 were zap- Fig. 2. Effects of vinpocetine, EHNA, milrinone, Ro20–1724 rinast (type 5) > Ro20–1724 (type 4) > EHNA (type 2) and zaprinast on the contraction induced by 0.3 M CCh in milrinone (type 3) > vinpocetine (type 1) (P<0.05). porcine iris sphincter. Preparations were precontracted with Effects of various PDE inhibitors on cGMP and cAMP CCh and the indicated agents were added cumulatively. The contents: In the presence of CCh (0.3 M), vinpocetine, mil- maximum contraction induced by 0.3 M CCh in the absence rinone and Ro20–1724 increased cAMP contents. With of these agents was taken as 100%. Each point represents the these drugs, cAMP contents increased by 1.47 (vinpocet- mean of 5–8 preparations. Vertical bars indicate S.E.M. ine), 1.6 (milrinone) and 1.5 (Ro20–1724) times above rest- ing levels. cAMP contents were not affected by EHNA and DISCUSSION zaprinast (Fig. 3A). In contrast, zaprinast and EHNA both increased cGMP contents by 1.57 (EHNA) and 2.15 (zapri- Physiological iris contractions are mediated by the nona- nast) times above resting levels. cGMP contents were not drenergic, noncholinergic nervous system in addition to the affected by vinpocetine, milrinone or Ro20–1724 (Fig. 3B). adrenergic, cholinergic nervous system. The stimulators of adenyl cyclase, -adrenoceptor agonists [22, 24] and adrenomedullin [26], induce relaxation by increasing cAMP contents, and the stimulators of guanylyl cyclase, atrial PHOSPHODIESTERASE INHIBITORS IN IRIS SPHINCTER 1451 natriuretic peptide [9] and nitric oxide [16], induce relax- Table 1. IC50 and maximum relaxation concentrations for various selective PDE inhibitors in porcine iris sphincter treated with 0.3 ation via cGMP in the iris sphincter muscle. In the present M CCh study, forskolin and SNP inhibited the muscarinic agonist carbachol (CCh)-induced contraction in a concentration- Agent IC50 (M) Maximum relaxation (%) n dependent manner (Fig. 1). These results suggest that the Vinpocetine >30 43.9 4.6 5 cAMP/adenyl cyclase and cGMP/guanylyl cyclase path- EHNA 92.4 (89.4 –98.6) 53.9 1.6 6 ways are both involved in the relaxation of porcine iris Milrinone 99.4 (54.0 – >100) 52.8 4.0 8 Ro20–1724 58.3 (36.9 – 95.0) 58.4 3.4 6 sphincter muscle.
Recommended publications
  • Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della ricerca- Università di Roma La Sapienza Inflammation, Vol. 39, No. 3, June 2016 (# 2016) DOI: 10.1007/s10753-016-0359-6 ORIGINAL ARTICLE Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy Luigi Di Luigi,1 Clarissa Corinaldesi,1 Marta Colletti,1 Sabino Scolletta,2 Cristina Antinozzi,1 Gabriella B. Vannelli,3 Elisa Giannetta,4 Daniele Gianfrilli,4 Andrea M. Isidori,4 Silvia Migliaccio,1 Noemi Poerio,5 Maurizio Fraziano,5 Andrea Lenzi,4 and Clara Crescioli1,6 Abstract—T helper 1 (Th1) type cytokines and chemokines are bioactive mediators in inflammation underling several diseases and co-morbid conditions, such as cardiovascular and metabolic disorders. Th1 chemokine CXCL10 participates in heart damage initiation/progression; cardioprotection has been recently associated with sildenafil, a type 5 phosphodiesterase inhibitor. We aimed to evaluate the effect of sildenafil on CXCL10 in inflammatory conditions associated with diabetic cardiomyopathy. We analyzed: CXCL10 gene and protein in human cardiac, endothelial, and immune cells challenged by pro-inflammatory stimuli with and without sildenafil; serum CXCL10 in diabetic subjects at cardiomy- opathy onset, before and after 3 months of treatment with sildenafil vs. placebo. Sildenafil significantly −7 decreased CXCL10 protein secretion (IC50 =2.6×10 ) and gene expression in human cardiomyocytes and significantly decreased circulating CXCL10 in subjects with chemokine basal level ≥ 930 pg/ml, the cut-off value as assessed by ROC analysis. In conclusion, sildenafil could be a pharmacologic tool to control CXCL10-associated inflammation in diabetic cardiomyopathy.
    [Show full text]
  • Effects of Phosphodiesterase Inhibitors on Human Lung Mast Cell and Basophil Function
    British Journal of Pharmacology (1997) 121, 287 ± 295 1997 Stockton Press All rights reserved 0007 ± 1188/97 $12.00 Eects of phosphodiesterase inhibitors on human lung mast cell and basophil function Marie C. Weston, Nicola Anderson & 1Peter T. Peachell Department of Medicine & Pharmacology, University of Sheeld, Royal Hallamshire Hospital (Floor L), Glossop Road, Sheeld S10 2JF 1 The non-hydrolysable cyclic AMP analogue, dibutyryl (Bu2)-cyclic AMP, inhibited the stimulated release of histamine from both basophils and human lung mast cells (HLMC) in a dose-dependent manner. The concentrations required to inhibit histamine release by 50% (IC50) were 0.8 and 0.7 mM in basophils and HLMC, respectively. The cyclic GMP analogue, Bu2-cyclic GMP, was ineective as an inhibitor of histamine release in basophils and HLMC. 2 The non-selective phosphodiesterase (PDE) inhibitors, theophylline and isobutyl-methylxanthine (IBMX) inhibited the IgE-mediated release of histamine from both human basophils and HLMC in a dose-dependent fashion. IBMX and theophylline were more potent inhibitors in basophils than HLMC. IC50 values for the inhibition of histamine release were, 0.05 and 0.2 mM for IBMX and theophylline, respectively, in basophils and 0.25 and 1.2 mM for IBMX and theophylline in HLMC. 3 The PDE 4 inhibitor, rolipram, attenuated the release of both histamine and the generation of sulphopeptidoleukotrienes (sLT) from activated basophils at sub-micromolar concentrations but was ineective at inhibiting the release of histamine and the generation of both sLT and prostaglandin D2 (PGD2) in HLMC. Additional PDE 4 inhibitors, denbufylline, Ro 20-1724, RP 73401 and nitraquazone, were all found to be eective inhibitors of mediator release in basophils but were ineective in HLMC unless high concentrations (1 mM) were employed.
    [Show full text]
  • Chapter Introduction
    VU Research Portal Trypanosoma brucei phosphodiesterase B1 as a drug target for Human African Trypanosomiasis Jansen, C.J.W. 2015 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Jansen, C. J. W. (2015). Trypanosoma brucei phosphodiesterase B1 as a drug target for Human African Trypanosomiasis. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 05. Oct. 2021 An introduction into phosphodiesterases and their potential role as drug targets for neglected diseases Chapter 1 4 CHAPTER 1 1.1 Human African Trypanosomiasis Human African Trypanomiasis (HAT), also known as African sleeping sickness, is a deadly infectious disease caused by the kinetoplastid Trypanosoma
    [Show full text]
  • Inhibitors of Cyclic-GMP Phosphodiesterase Alter Excitation of Limulus Ventral Photoreceptors in Ca2+-Dependent Fashion
    The Journal of Neuroscience, October 1995, 75(10): 6586-6591 Inhibitors of Cyclic-GMP Phosphodiesterase Alter Excitation of Limulus Ventral Photoreceptors in Ca2+-Dependent Fashion Edwin C. Johnsonifa and Peter M. O’Day* ‘Department of Physiology, Marshall University School of Medicine, Huntington, West Virginia 257559340 and *Institute of Neuroscience and Department of Biology, University of Oregon, Eugene, Oregon 97403-1254 We have examined the hypothesis that Ca*+-dependent cy- 1994) consistent with the idea that the following events occur clic-GMP metabolism may play a role in visual transduction in phototransduction. Activation of visual pigment, rhodopsin, in Limulus photoreceptors. Although phosphoinositide hy- by light activates a G-protein, stimulating hydrolysis of phos- drolysis is central to phototransduction and phosphoinos- phatidylinositol 4,5-bisphosphate(PIP,) by phospholipaseC; itide-dependent Ca2+-mobilization seems to be required for this createscytosolic inositol 1,4,5trisphosphate(IP,), the trig- transduction, the subsequent steps leading to ion channel ger for mobilization of intracellular Ca2+ and elevation of gating (the immediate cause of excitation) are not under- [CaZ+,].In Limulus photoreceptors,Ca2+-mobilization causes ex- stood. Channels normally opened in response to light can citation by opening plasma membrane channels; however, the be opened in excised membrane patches by cGMP but not link betweenCa*+ elevation and channel gating remainsobscure. by Ca*+, suggesting that cGMP acts as a channel ligand in Electrophysiological evidence implicates cGMP involvement excitation. in Limulus transduction (Johnsonet al., 1986; Bacigalupo et al., Using phosphodiesterase inhibitors, we investigated 1991; Feng et al., 1991). The observation that light-activated whether changes in cGMP metabolism could affect exci- channels are gated selectively by cGMP and not by Ca2+(Ba- tation.
    [Show full text]
  • Repurposing Erectile Dysfunction Drugs Tadalafil and Vardenafil to Increase Bone Mass
    Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass Se-Min Kima,b,1, Charit Tanejaa,b, Helena Perez-Penac, Vitaly Ryua,b, Anisa Gumerovaa,b, Wenliang Lic, Naseer Ahmada,b, Ling-Ling Zhua,b, Peng Liua,b, Mehr Mathewa,b, Funda Korkmaza,b, Sakshi Geraa,b, Damini Santa,b, Elina Hadeliaa,b, Kseniia Ievlevaa,b,d, Tan-Chun Kuoa,b, Hirotaka Miyashitaa,b, Li Liue,f, Irina Tourkovae,f, Sarah Stanleyb, Daria Liznevaa,b, Jameel Iqbala,b, Li Suna,b, Ronald Tamlerb, Harry C. Blaire,f, Maria I. Newa,g,1, Shozeb Haiderc, Tony Yuena,b,2, and Mone Zaidia,b,2 aThe Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029; cDepartment of Pharmaceutical and Biological Chemistry, University College London School of Pharmacy, WC1N 1AX London, United Kingdom; dDepartment of Reproductive Health, Scientific Center for Family Health and Human Reproduction Problems, 664003 Irkutsk, Russian Federation; eDepartment of Pathology, Pittsburgh Veterans Affairs Healthcare System, Pittsburgh, PA 15240; fDepartment of Pathology, University of Pittsburgh, Pittsburgh, PA 15261; and gDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029 Contributed by Maria I. New, April 17, 2020 (sent for review January 27, 2020; reviewed by Yousef Abu-Amer, Fayez F. Safadi, and Mei Wan) We report that two widely-used drugs for erectile dysfunction, bone mass, respectively (18, 19). Likewise, soluble guanylate cy- tadalafil and vardenafil, trigger bone gain in mice through a com- clase has also been targeted for bone gain (20, 21).
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • PDE1B KO Confers Resilience to Acute Stress-Induced Depression-Like Behavior
    PDE1B KO confers resilience to acute stress-induced depression-like behavior A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Molecular and Developmental Biology Program of the College of Medicine by Jillian R. Hufgard B.S. Rose-Hulman Institute of Technology April 2017 Committee Chair: Charles V. Vorhees, Ph.D. ABSTRACT Phosphodiesterases (PDE) regulate secondary messengers such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by hydrolyzing the phosphodiester bond. There are over 100 PDE proteins that are categorized into 11 families. Each protein family has a unique tissue distribution and binding affinity for cAMP and/or cGMP. The modulation of different PDEs has been used to treat several disorders: inflammation, erectile dysfunction, and neurological disorders. Recently, PDE inhibitors were implicated for therapeutic benefits in Alzheimer’s disease, depression, Huntington’s disease, Parkinson’s disease, schizophrenia, and substance abuse. PDE1B is found in the caudate-putamen, nucleus accumbens, dentate gyrus, and substantia nigra–areas linked to depression. PDE1B expression is also increased after acute and chronic stress. Two ubiquitous Pde1b knockout (KO) mouse models, both removing part of the catalytic region, decreased immobility on two acute stress tests associated with depression-like behavior; tail suspension test (TST) and forced swim test (FST). The decreases in immobility suggest resistance to depression-like behavior, and these effects were additive when combined with two current antidepressants, fluoxetine and bupropion. The resistance to induced immobility was seen when PDE1B was knocked down during adolescence or earlier.
    [Show full text]
  • Rolipram, but Not Siguazodan Or Zaprinast, Inhibits the Excitatory Noncholinergic Neurotransmission in Guinea-Pig Bronchi
    Eur Respir J, 1994, 7, 306–310 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07020306 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi Y. Qian, V. Girard, C.A.E. Martin, M. Molimard, C. Advenier Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neuro- Faculté de Médecine Paris-Ouest Labora- transmission in guinea-pig bronchi. Y. Qian, V. Girard C.A.E. Martin, M. Molimard, toire de Pharmacologie, Paris, France. C. Advenier. ERS Journals Ltd 1994. ABSTRACT: Theophylline has been reported to inhibit excitatory noncholinergic Correspondence: C. Advenier Faculté de Médecine Paris-Ouest but not cholinergic-neurotransmission in guinea-pig bronchi. As theophylline might Laboratoire de Pharmacologie exert this effect through an inhibition of phosphodiesterases (PDE), and since many 15, Rue de l'Ecole de Médecine types of PDE have now been described, the aim of this study was to investigate the F-75270 Paris Cedex 06 effects of three specific inhibitors of PDE on the electrical field stimulation (EFS) France of the guinea-pig isolated main bronchus in vitro. The drugs used were siguazo- dan, rolipram and zaprinast, which specifically inhibit PDE types, III, IV and V, Keywords: C-fibres respectively. neuropeptides Guinea-pig bronchi were stimulated transmurally with biphasic pulses (16 Hz, 1 phosphodiesterase inhibitors ms, 320 mA for 10 s) in the presence of indomethacin 10-6 M and propranolol 10-6 Received: March 11 1993 M. Two successive contractile responses were observed: a rapid cholinergic con- Accepted after revision August 8 1993 traction, followed by a long-lasting contraction due to a local release of neuropep- tides from C-fibre endings.
    [Show full text]
  • Integrated Technologies for the Characterization Of
    Integrated technologies for the characterization of phosphodiesterase (PDE) inhibitors Edmond Massuda, Lisa Fleet, Benjamin Lineberry, Laurel Provencher, Abbie Esterman, Dhanrajan Tiruchinapalli, Faith Gawthrop, Christopher Spence, Rajneesh P. Uzgare, Scott Perschke, Seth Cohen, and Hao Chen. 618.01/XX63 Caliper Life Sciences, a PerkinElmer Company, 7170 Standard Drive, Hanover, Maryland, 21076 USA Abstract Phosphodiesterases (PDEs) are a class of signal transduction enzymes regulating various cellular functions and disease Results Results progressions in a number of central or peripheral nervous system-related disorders. For example, these enzymes are involved in neurological diseases including psychosis in schizophrenia, multiple sclerosis and other neurodegenerative PDE1A PDE1B PDE2A PDE3A PDE3B PDE4A1A PDE4B1 Ki and kinact determination using 3D Fit Model 110 110 110 110 110 100 110 110 100 100 100 Percent of Maximum Activity by Time 100 conditions. Thus, safe and highly selective PDE inhibitors or modulators are becoming an important class of disease 100 90 100 90 90 90 90 90 80 90 80 80 80 80 modifying therapeutic agents. We have developed an integrated platform which includes Caliper LabChip™ microfluidic 80 70 80 70 70 70 70 70 60 70 60 60 60 60 mobility-shift assays measuring fluorescent analogs of cAMP and cGMP in conjunction with a cellular assay 60 60 50 50 50 50 50 50 50 40 40 40 40 characterizing intracellular signal transduction in cells modulated by PDE inhibitors. These technologies are useful in 40 40 40 30 30 30 30 %%
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • WO 2015/195228 Al 23 December 2015 (23.12.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/195228 Al 23 December 2015 (23.12.2015) P O P C T (51) International Patent Classification: 02215 (US). ZHANG, Yun [CN/US]; 6 Sawmill Road, C07D 403/14 (2006.01) C07D 473/16 (2006.01) Acton, MA 0 1720 (US). ZHOU, Tianjun [US/US]; 55 Home Road, Belmont, MA 02478 (US). (21) International Application Number: PCT/US2015/030576 (74) Agents: PETERSON, Gretchen, S. et al; Ariad Pharma ceuticals, INC., 26 Landsdowne Street, Cambridge, MA (22) International Filing Date: 02139 (US). 13 May 2015 (13.05.2015) (81) Designated States (unless otherwise indicated, for every (25) Language: English Filing kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/014,500 19 June 2014 (19.06.2014) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (71) Applicant: ARIAD PHARMACEUTICALS, INC. KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, [US/US]; 26 Landsdowne Street, Cambridge, MA 02139 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (US). PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors; and TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]